Professional Associations

This page includes news coverage of medical associations and medical societies. Use these links to find focused news coverage from specific organizations: Cardiology Associations, Healthcare Associations, Radiology Associations.

ACC raises red flags over telehealth, payment reform and the cardiologist shortage
"We need telehealth the way we had it for COVID," Cathie Biga told Cardiovascular Business at TCT 2025. "We don't want to go back to having it so restricted."
COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination
Adults are three times as likely to have a heart attack or stroke after a COVID-19 infection than when they are healthy. The risks are even greater for the flu.
Key takeaways for interventional cardiology from TCT 2025
B. Hadley Wilson, MD, talked to Cardiovascular Business about several standout late-breaking clinical trials presented at TCT 2025. Topics of those trials included drug-coated balloons, TAVR valve durability, pulmonary embolism treatments and much more.
More good news for renal denervation: FDA-approved systems linked to positive long-term data
New data on the RDN systems from Recor Medical and Medtronic confirmed that this relatively new technology brings long-term relief to patients with uncontrolled hypertension.
Evoque TTVR system linked to favorable outcomes in new real-world analysis
Researchers tracked data from more than 1,000 real-world patients, focusing on 30-day safety and efficacy outcomes. The group shared its findings at TCT 2025 in San Francisco.

Many older heart failure patients are alone and vulnerable—what can be done to help?

Older heart failure patients with no immediate family are especially vulnerable. Additional interventions may be necessary to reach these patients and provide the best care possible.

Raj Makkar, MD, director, interventional cardiology, director, Interventional Cardiology Research Program and professor of medicine, Smidt Heart Institute, Cedars-Sinai Hospital, presented the late-breaking Align-AR clinical trial at ACC 2025 on the first 500 patients treated for aortic regurgitation using the Jena Valve transcatheter aortic valve replacement (TAVR) device.

First 500 patients in Align-AR trial using TAVR for pure aortic regurgitation show strong outcomes

Raj Makkar, MD, Cedars-Sinai, explains the late-breaking data from the Align-AR trial on the first 500 patients treated for aortic regurgitation using the Jena Valve TAVR device.

American College of Cardiology (ACC) President Christopher Kramer, MD, FACC, spoke at a hearing of the U.S. House Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies March 9 to urge lawmakers to allocate full funding for the Cardiomyopathy Health Education, Awareness, Research, and Training in Schools (HEARTS) Act (H.R.6829). It was signed into law in the closing weeks of the Biden administration. #ACC

ACC testifies in Washington to get funding for the HEARTS Act amid big cuts to healthcare

ACC President Christopher Kramer, MD, testified before a Congressional subcommittee to ask for federal funding to support a new law aimed at reducing sudden cardiac arrest deaths, and to support NIH research.

Michael Reardon, MD, explained the low-risk Evolut 5-year results of TAVR vs. SAVR at ACC 2025. #ACC #ACC25 #ACC2025

5-year Evolut Low Risk Data: Durable clinical outcomes, outstanding valve performance

Sponsored by Medtronic

The late-breaking five-year results of the Evolut Low-Risk Trial presented at ACC.25 showed positive results for the Evolut TAVR system when compared to SAVR.

ACC President Cathie Biga, MSN, president/CEO Cardiovascular Management of Illinois, discusses a letter ACC sent to Health and Human Services Secretary Robert F. Kennedy Jr. stressing some of the big challenges facing healthcare and cardiology from Trump administration policies.

'We need to come together as a nation': Why science, not politics, should guide healthcare policies

ACC Immediate Past President Cathie Biga spoke to Cardiovascular Business about some of the challenges healthcare faces in the wake of mass layoffs and significant funding cuts put in place by the Trump administration.

FDA clears new device for enabling access to the heart’s surface without an exposed needle

CardioVia's ViaOne technology includes a blunt-tip needle that remains concealed to help interventional cardiologists and electrophysiologists treat cardiac arrhythmias with a reduced risk of perforation or any other complications.

Richard Kovacs, MD, MACC, chief medical officer, American College of Cardiology (ACC), former ACC president, and professor of clinical medicine, Indiana University School of Medicine, explains the most important late-breaking cardiology pharmacology trials at the ACC 2025 meeting. #ACC25 #ACC2025

Late-breaking cardiovascular drug trials took center stage at ACC.25

Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.

Deaths after TAVR are on the rise: Is the pandemic to blame or should cardiologists be concerned?

COVID-19 may help explain the increased rates of cardiac and noncardiac mortality among TAVR patients, but there are several other factors to consider as well. Researchers explored nearly 11 years of STS/ACC registry data to learn more.

Professional Associations

ACC raises red flags over telehealth, payment reform and the cardiologist shortage

COVID-19, other infections linked to major cardiovascular risks—researchers push for vaccination

Key takeaways for interventional cardiology from TCT 2025

More good news for renal denervation: FDA-approved systems linked to positive long-term data

Evoque TTVR system linked to favorable outcomes in new real-world analysis